miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review
Breast cancer is the most common type of lethal cancer in women globally. Women have a 1 in 8 chance of developing breast cancer in their lifetime. Among the four primary molecular subtypes (luminal A, luminal B, HER2+, and triple-negative), HER2+ accounts for 20–25 % of all breast cancer and is rat...
Main Authors: | Thanh Hoa Vo, Esam EL-Sherbieny Abdelaal, Emmet Jordan, Orla O'Donovan, Edel A. McNeela, Jai Prakash Mehta, Sweta Rani |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-03-01
|
Series: | Biochemistry and Biophysics Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580823001693 |
Similar Items
-
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01) -
Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
by: Katrin Almstedt, et al.
Published: (2023-02-01) -
HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01) -
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
by: Elena Díaz-Rodríguez, et al.
Published: (2021-12-01) -
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
by: Marina Popović, et al.
Published: (2023-05-01)